SeptiCyte RAPID demonstrated superior performance compared to procalcitonin and C-reactive protein in detecting sepsis among critically ill patients with hospital-acquired infections.
Greer Massey, PhD, chief scientific officer at Molecular Designs, shares insights on how labs are affected by the rule’s reversal and how they can prepare for future regulatory changes.
The infrared dye antibody conjugates aim to expand human phenotyping experiments innovation and make high-parameter flow cytometry more accessible.
The collaboration combines CAP/CLIA-certified molecular testing with ICH-compliant stability storage and biorepository services.
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
